Stryker Corporation Forecasted to Post FY2017 Earnings of $6.50 Per Share (SYK)

Stryker Corporation (NYSE:SYK) – Equities researchers at William Blair lifted their FY2017 EPS estimates for Stryker in a note issued to investors on Tuesday. William Blair analyst K. Krum now expects that the medical technology company will post earnings per share of $6.50 for the year, up from their previous forecast of $6.46. William Blair also issued estimates for Stryker’s Q4 2017 earnings at $1.97 EPS, Q1 2018 earnings at $1.56 EPS, Q3 2018 earnings at $1.76 EPS and FY2018 earnings at $7.15 EPS.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The business’s revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.39 EPS.

SYK has been the topic of several other reports. SunTrust Banks restated a “buy” rating and set a $161.00 target price on shares of Stryker in a research report on Monday, October 2nd. Oppenheimer set a $156.00 target price on shares of Stryker and gave the company a “hold” rating in a research report on Monday, October 30th. Canaccord Genuity upped their target price on shares of Stryker from $155.00 to $162.00 and gave the company a “buy” rating in a research report on Friday, October 27th. Zacks Investment Research cut shares of Stryker from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Finally, Cowen set a $160.00 target price on shares of Stryker and gave the company a “buy” rating in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company. Stryker currently has an average rating of “Hold” and an average target price of $156.60.

Shares of Stryker (NYSE SYK) opened at $159.54 on Wednesday. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. The stock has a market cap of $59,710.00, a PE ratio of 34.02, a PEG ratio of 2.30 and a beta of 0.78. Stryker has a 1 year low of $119.17 and a 1 year high of $164.20.

Hedge funds have recently modified their holdings of the business. Coldstream Capital Management Inc. grew its stake in Stryker by 3.7% in the 2nd quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock worth $2,421,000 after acquiring an additional 626 shares in the last quarter. Retirement Systems of Alabama grew its stake in Stryker by 2.5% in the 3rd quarter. Retirement Systems of Alabama now owns 234,870 shares of the medical technology company’s stock worth $33,356,000 after acquiring an additional 5,656 shares in the last quarter. Toronto Dominion Bank grew its stake in Stryker by 25.8% in the 2nd quarter. Toronto Dominion Bank now owns 105,403 shares of the medical technology company’s stock worth $14,625,000 after acquiring an additional 21,585 shares in the last quarter. Colonial Trust Advisors grew its stake in Stryker by 56.1% in the 2nd quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock worth $3,254,000 after acquiring an additional 8,426 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. grew its stake in Stryker by 3.1% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 55,255 shares of the medical technology company’s stock worth $7,847,000 after acquiring an additional 1,683 shares in the last quarter. Institutional investors and hedge funds own 74.90% of the company’s stock.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the transaction, the insider now directly owns 83,207 shares in the company, valued at approximately $12,925,375.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.40% of the company’s stock.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 1.18%. This is an increase from Stryker’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Thursday, December 28th. Stryker’s dividend payout ratio is presently 40.09%.

ILLEGAL ACTIVITY NOTICE: “Stryker Corporation Forecasted to Post FY2017 Earnings of $6.50 Per Share (SYK)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/11/stryker-corporation-forecasted-to-post-fy2017-earnings-of-6-50-per-share-syk.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply